Abbott Laboratories

ABT · NYSE · USD

$97.50+0.84%+$0.81

Close · October 2, 2026

At a glance

Revenue growth
+5.67%
2025 vs 2024
Net income growth
−51.32%
2025 vs 2024
Net margin
14.7%
2024: 31.9%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

ItemQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Total revenue12,59311,16411,45911,36911,14210,35810,97410,63510,3779,96410,24110,143
Cost of revenue5,3254,8904,9135,0754,8544,4684,8804,6984,6034,4634,5004,605
Gross profit7,2686,2746,5466,2946,2885,8906,0945,9375,7745,5015,7415,538
Selling, general and administrative3,8663,5812,9272,9032,9452,9142,7252,7602,7972,8272,5372,601
Research and development892767720766725716728713698684578672
Operating income1,8521,5042,4772,2052,1981,8402,1761,9941,8081,5182,1451,769
EBIT1,8521,5042,4772,2052,1981,8402,1761,9941,8081,5182,1451,769
EBITDA2,9122,3073,2692,9962,9752,5962,9832,7952,6132,3232,9582,593
Interest expense351174120121121131136142140141159166
Pre-tax income1,5241,4492,3582,1802,1501,7782,0301,9401,6071,4361,7951,671
Income tax596372582536371453-7,199294305211201235
Net income9281,0771,7761,6441,7791,3259,2291,6461,3021,2251,5941,436
Net income to common shareholders9281,0771,7521,6441,7791,3259,2271,6461,3021,2251,5881,431
Basic EPS0.530.621.000.941.020.765.280.950.750.700.910.82
Diluted EPS0.530.611.000.941.010.765.260.940.740.700.910.82
Average shares (basic)1,7401,7421,7471,7421,7431,7391,7461,7391,7431,7401,7481,739
Average shares (diluted)1,7431,7471,7471,7491,7511,7471,7461,7481,7511,7501,7481,748
Dividend per share0.630.630.630.590.590.590.590.550.550.550.550.51